- BeiGene ( NASDAQ: BGNE ) signed a strategic agreement with McKesson's ( NYSE: MCK ) unit Ontada to improve U.S. community oncology care by developing real-world evidence (RWE) data and tools to help increase access to affordable therapies.
- The partnership will be led by Ontada and focus on developing and implementing RWE to improve community education on the financial impact and value of oncolytics and improve patient access to oncology medicines, BeiGene said in an Aug. 15 press release.
- "BeiGene aims to bring 10 molecules per year to the clinic starting in 2023 and, as this research advances, we’re delighted to form this strategic partnership with McKesson, which shares the same vision as BeiGene for improving the care of cancer patients," said Christiane Langer, senior vice president of Global Medical Affairs, ex-China, BeiGene.
For further details see:
BeiGene, McKesson team up to develop data, tools for US community oncology care